(12) **Translation of European patent specification**

(11) **NO/EP 3063143 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 405/14 (2006.01) ***C07D 241/20 (2006.01)*** ***C07D 403/06 (2006.01)***
A61K 31/4418 (2006.01) ***C07D 401/04 (2006.01)*** ***C07D 405/04 (2006.01)***
A61P 35/00 (2006.01) ***C07D 401/06 (2006.01)*** ***C07D 409/04 (2006.01)***
C07D 213/73 (2006.01) ***C07D 401/12 (2006.01)*** ***C07D 413/14 (2006.01)***

Norwegian Industrial Property Office

(21)	Translation Published	2018.10.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.05.16
(86)	European Application Nr.	14800191.0
(86)	European Filing Date	2014.10.29
(87)	The European Application's Publication Date	2016.09.07
(30)	Priority	2013.11.01, US, 201361898761 P 2014.10.11, WO, PCT/CN14/088409
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
(73)	Proprietor	Novartis AG, Lichtstrasse 35, 4056 Basel, CH-Sveits
(72)	Inventor	BAGDANOFF, Jeffrey T., Novartis Institutes for BioMedical Research Inc. Emeryville Site 5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA DING, Yu, Novartis Institutes for BioMedical Research Inc. Emeryville Site 5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA HAN, Wooseok, Novartis Institutes for BioMedical Research Inc. Emeryville Site 5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA HUANG, Zilin, 133 Beach Park Blvd., Foster City, California 94404, US-USA JIANG, Qun, Suzhou Novartis Pharma Technology Co. Ltd.18 Tonglian Road Riverside Industrial Park Changshu Economic Development Zone Changshu, Jiangsu 215537, CN-Kina JIN, Jeff Xianming, Novartis Institutes for BioMedical Research Inc. Emeryville Site 5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA KOU, Xiang, Novartis Pharmaceuticals (China)Building 8 898 Halei RoadPudong District, Shanghai 201203, CN-Kina LEE, Patrick, Novartis Institutes for BioMedical Research Inc.Emeryville Site5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA LINDVALL, Mika, Novartis Institutes for BioMedical Research Inc.Emeryville Site5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA MIN, Zhongcheng, Suzhou Novartis Pharma Technology Co. Ltd.18 Tonglian Road Riverside Industrial ParkChangshu Economic Development Zone Changshu, Jiangsu 215537, CN-Kina PAN, Yue, Novartis Institutes for BioMedical Research Inc. Emeryville Site5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA PECCHI, Sabina, 5834 Merriewood Drive, Oakland, California 94611, US-USA

PFISTER, Keith Bruce, Novartis Institutes for BioMedical Research Inc. Emeryville Site5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA
POON, Daniel, Novartis Institutes for BioMedical Research Inc. Emeryville Site5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA
RAUNIYAR, Vivek, Novartis Institutes for BioMedical Research Inc. Emeryville Site 5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA
WANG, Xiaojing Michael, Novartis Institutes for BioMedical Research Inc. Emeryville Site 5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA
ZHANG, Qiong, Novartis Institutes for BioMedical Research Inc. Emeryville Site5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA
ZHOU, Jianguang, Suzhou Novartis Pharma Technology Co. Ltd.18 Tonglian Road Riverside Industrial Park Changshu Economic Development Zone Changshu, Jiangsu 215537, CN-Kina
ZHU, Shejin, Novartis Institutes for BioMedical Research Inc. Emeryville Site 5300 Chiron Way Bldg. 4, Emeryville, California 94608, US-USA

(74) Agent or Attorney ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

---

(54) Title **AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS**

(56) References Cited: WO-A2-2004/016597

Patentkrav

1. Forbindelse med formel (I):



(I)

eller et farmasøytisk akseptabelt salt derav, hvori:

R^1 er en eventuelt substituert gruppe valgt fra C_{3-8}-sykloalkyl, 5-8-leddet heterosyklyl inneholdende 1-2 heteroatomer valgt fra N, O og S som ringledd, fenyl, - SO_2-fenyl, -C(O)-fenyl, -$C(R^8)_2$-fenyl, og 5-6-leddet heteroarylring, hvori heterosyklylet og heteroarylet inneholder 1-2 heteroatomer valgt fra N, O og S som ringledd,

og hvori de valgfrie substituentene for R^1 er 1–3 grupper uavhengig valgt fra D, halo, hydroksy, amino, -$N(R^8)_2$, CN, C_{1-4}-alkyl, C_{1-4}-alkoksy, -S(C_{1-4}-alkyl), C_{1-4}-haloalkyl, C_{1-4}-haloalkoksy, C_{3-6}-sykloalkyl, 3–6-leddet heterosyklyl inneholdende 1–2 heteroatomer valgt fra N, O og S, okso (unntatt på aromatiske ringer), $COOR^8$, $CON(R^8)_2$, -NR^8-C(O)R^8, -NR^8-C(O)OR^8-SO_2R^8, -$NR^8SO_2R^8$, og $SO_2N(R^8)_2$, hvor hver R^8 uavhengig er H eller C_{1-4}-alkyl;

L er



hvori R" er metyl eller etyl, og eventuelt er substituert med fluor, amino, hydroksy, metylamino, etylamino, dimetylamino, -$OP(O)(OH)_2$, metoksy eller etoksy;

X og Y er uavhengig valgt fra H, D, halo, CN, amino, hydroksy, C_{1-4}-alkyl, C_{1-4}-haloalkyl, C_{1-4}-alkoksy, og C_{1-4}-haloalkoksy;

R^2 er H, C_{1-4}-alkyl, eller aryl-C_{1-2}-alkyl-, hvori aryl og C_{1-4}-alkyl eventuelt er substituert med halo, CN, C_{1-4}-alkyl, C_{1-4}-haloalkyl, C_{3-6}-sykloalkyl, C_{1-4}-alkoksy, C_{1-4}-haloalkoksy, eller C_{1-4}-alkylsulfonyl; eller

R^2 og L er bundet sammen for å danne en heterosyklisk gruppe valgt fra morfolin, piperidin, tiomorfolin, piperazin, pyrrolidin som er knyttet til R^1 og som også eventuelt er substituert med én eller to grupper uavhengig valgt fra C_{1-4}-alkyl, C_{1-4}-alkoksy, okso, CN, $COOR^7$, $CON(R^7)_2$, og -SO_2R^7, hvor hver R^7 uavhengig er H eller C_{1-4}-alkyl;

Z er N eller CR^4;
R^4 er H, D, halo, C_{1-4}-alkyl, C_{1-4}-haloalkyl, eller C_{1-4}-alkoksy;
R^5 er valgt fra -C(O)-R^{5a} og R^{5a}; hvori R^{5a} er et eventuelt substituert C_{3-8}-sykloalkyl, C_{3-8}-sykloalkenyl, mettet eller umettet 3–8-leddet heterosyklisk ring inneholdende 1–2 heteroatomer valgt fra N, O og S, fenyl eller 5–6-leddet heteroarylring inneholdende 1–3 heteroatomer valgt fra N, O og S, hvori de eventuelle substituentene for R^5 er 1–4 grupper uavhengig valgt fra D, halo, hydroksy, amino, CN, C_{1-4}-alkyl, C_{1-4}-alkoksy, C_{1-4}-haloalkyl, C_{1-4}-hydroksyalkyl, C_{1-4}-haloalkoksy, C_{3-6}sykloalkyl, 3–6-leddet heterosyklyl inneholdende 1–2 heteroatomer valgt fra N, O og S, okso (unntatt på atomatiske ringer), -$COOR^9$, -$C(O)R^9$, $CON(R^9)_2$, -$NR^9C(O)R^9$, -$NR^9CO_2R^9$, -SO_2R^9, -$NR^9SO_2R^9$, og -$SO_2N(R^9)_2$, hvor hver R^9 uavhengig er H eller C_{1-4}-alkyl eventuelt substituert med 1–3 grupper uavhengig valgt fra D, halo, OH, NH_2, NHMe og NMe_2; og to substituenter på det samme eller tilstøtende karbonatomer til R^5 kan eventuelt tas sammen for å danne en 5–6-leddet ring som kan være mettet eller aromatisk og inneholder 1–2 heteroatomer valgt fra N, O og S og som eventuelt kan substitueres med 1–2 grupper uavhengig valgt fra D, Me, halo, OH, okso, O(C_{1-4}-alkyl), NH_2, C_{1-4}-alkylamino, di(C_{1-4}-alkyl)amino; og
R^6 er H, D, halo, C_{1-4}-alkyl, eller C_{1-4}-haloalkyl.

2. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvor Z er N.

3. Forbindelsen ifølge krav 1 eller krav 2, eller et farmasøytisk akseptabelt salt derav, hvori R^2 er H eller Me.

4. Forbindelse ifølge et hvilket som helst av krav 1–3, eller et farmasøytisk akseptabelt salt derav, hvori R^6 er H.

5. Forbindelse ifølge hvilket som helst av kravene 1 til 4 eller et farmasøytisk akseptabelt salt derav, hvori R^5 er valgt fra -C(O)-R^{5a} og R^{5a}; hvori R^{5a} er valgt fra C_{3-8}sykloalkyl, 5–8-leddet heterosyklyl inneholdende 1-2 heteroatomer valgt fra N, O og S, fenyl, og 5–6-leddet heteroaryl, og er eventuelt substituert med 1–3 grupper uavhengig valgt fra D, halo, CN, hydroksy, C_{1-4}-alkoksy, C_{1-4}-alkyl, C_{1-4}-haloalkyl, C_{1-4}-hydroksyalkyl, C_{1-4}-haloalkoksy, -SO_2R', -NR'-C(O)-R', og -$SO_2NR'_2$, hvor hver R' uavhengig er H eller C_{1-4}-alkyl.

6. Forbindelse ifølge hvilket som helst av kravene 1-4, eller et farmasøytisk akseptabelt salt derav, hvori R^5 er valgt fra -C(O)-R^{5a} og R^{5a}; hvori R^{5a} er valgt fra syklobutyl, syklopentyl, sykloheksyl, sykloheksenyl, tetrahydropyran, dihydropyran, tetrahydrofuran, oksetan, azetidin, pyrrolidin, piperidin, piperazin, morfolin, tetrahydrotiopyran (tiasykloheksan) og tetrahydrotiofuran (tiasyklopentan), idet hver av disse eventuelt er substituert med 1–3 grupper uavhengig valgt fra halo, D, CN, hydroksy, C_{1-4}-alkyl, C_{1-4}-alkoksy, C_{1-4}-haloalkyl, C_{1-4}-hydroksyalkyl, C_{1-4}-haloalkoksy, okso, $COOR^9$, $CON(R^9)_2$, -$NHC(O)R^9$, -$NHCOOR^9$, -$NHSO_2R^9$, og -SO_2R^9, hvor hver R^9 uavhengig er H eller C_{1-4}-alkyl.

7. Forbindelsen ifølge et hvilket som helst av kravene 1-6, eller et farmasøytisk akseptabelt salt derav, hvori R^1 er fenyl, og er eventuelt substituert med en til tre grupper uavhengig valgt fra halo, D, CN, C_{1-4}-alkoksy, C_{1-4}-alkyl, C_{1-4}-haloalkyl, C_{1-4}-haloalkoksy, -SO_2R', -$N(R')_2$, - NR'-C(O)-R', og -$SO_2NR'_2$, hvor hver R' uavhengig er H eller C_{1-4}-alkyl.

8. Forbindelsen ifølge krav 1–7, eller et farmasøytisk akseptabelt salt derav, hvori Y er H, metyl eller halo.

9. Forbindelsen ifølge krav 1, hvilken er en forbindelse med formel IB:



(IB)

hvori R^5 er en 4–7-leddet syklisk eter eller C_{5-6}-sykloalkyl, og R^5 kan substitueres med opptil fire grupper uavhengig valgt fra D, F, Cl, CN, amino, -CH_2OH, -NHC(O)Me, - NHCOOMe, -$NHSO_2$Me, Me, OMe, OH, oxo, Et, iPr, OEt, og CF_3;
Y er H, F, Cl, eller Me;
R^{10} er -CH_2-R*, hvor R* er H, -OH, F, -NH_2, -NHMe, -$OP(O)(OH)_2$, -NMe_2, eller -OMe; og
R^1 er fenyl, eventuelt substituert med 1–2 grupper uavhengig valgt fra halo, CN, C_{1-4}-alkyl, C_{1-4}-alkoksy, C_{1-4}-haloalkyl, C_{1-4}-haloalkoksy, $COOR^8$, $CON(R^8)_2$, og -SO_2R^8, hvor hver R^8 uavhengig er H eller C_{1-4}-alkyl;
eller et farmasøytisk akseptabelt salt derav.

10. Forbindelsen ifølge hvilket som helst av kravene 1-4 eller 9, hvori R^5er sykloheksyl substituert med 1–3 grupper uavhengig valgt fra D, F, Cl, CN, amino, Me, $NHSO_2Me$, NHCOMe, OMe, OH, Et, CN, $-CH_2OH$, og CF_3.

11. Forbindelse ifølge krav 1, hvori R^1 er fenyl substituert med 0, 1 eller 2 grupper uavhengig valgt fra F, Cl, Br, I, SMe, SO_2Me, og CH_3.

12. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, valgt fra gruppen bestående av:

	
	
	

	
	
	

	
	
	
	

	
	
	

	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	

	
	
	

	
	
	

	
	
	

	
	
	

	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

NH2
F
O
N
H
OH
F
F
F
N
N
O
NH2
F
O
N
H
F
Br
N
N
F
OH
NH2
F
O
N
H
F
Br
N
N
F
OH
NH2
F
O
N
H
F
I
N
N
F
OH
NH2
F
O
N
H
Br
N
N
OH
NH2
F
O
N
H
F
I
N
N
F
OH
NH2
F
O
N
H
F
I
N
N
O

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

NH2
F
O
N
H
Br
OH
Cl
O=S=O

	
	
	
	

	
	
	
	

	
	
	
	

NH2
F
O
N
H
OH
Cl
Br
F
F
O=S=O

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

13. Forbindelse ifølge krav 1, hvilken er:



eller et farmasøytisk akseptabelt salt derav.

14. Forbindelse ifølge krav 1, hvilken er:



,

eller et farmasøytisk akseptabelt salt derav.

15. Forbindelse ifølge krav 1, hvilken er:



,

eller et farmasøytisk akseptabelt salt derav.

16. Forbindelse ifølge krav 1, hvilken er:



,

eller et farmasøytisk akseptabelt salt derav.

17. Forbindelse ifølge krav 1, hvilken er 4-(3-amino-6-((1S, 3S, 4S)-3-fluor-4-hydroksysykloheksyl)pyrazin-2-yl)-N-((S)-1-(3-brom-5-fluorfenyl)-2-(metylamino) etyl)-2-fluorbenzamid i hydrokloridsaltform.

18. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1–17 eller et farmasøytisk akseptabelt salt derav, blandet med minst én farmasøytisk akseptabel bærer.

19. Sammensetning ifølge krav 18, ytterligere omfattende et terapeutisk virkestoff.

20. Forbindelse ifølge et hvilket som helst av kravene 1–17, eller et farmasøytisk akseptabelt salt derav, eller en farmasøytisk sammensetning ifølge krav 18 eller krav 19 til anvendelse i behandling av kreft.

21. Forbindelse eller sammensetning til anvendelse ifølge krav 20, hvori kreften er valgt fra adenom, blærekreft, hjernekreft, brystkreft, livmorhalskreft, kolorektal kreft, tykktarmskreft, epidermalt karsinom, follikkelkarsinom, urogenitale kreftformer, glioblastom, hode- og nakkekreft, Hodgkins sykdom, ikke-Hodgkins lymfom, hepatom, nyrekreft, lungekreft som småcellet eller ikke-småcellet lungekreft, leukemier som AML eller CML, multippel myelom, lymfoide lidelser, hudkreft inkludert melanom, nevroblastom, eggstokkreft, kreft i bukspyttkjertelen, prostatakreft, rektal kreft, sarkom, testikkelkreft og skjoldbruskkreft.

22. Forbindelse ifølge et hvilket som helst av kravene 1-17, eller et farmasøytisk akseptabelt salt derav i kombinasjon med en forbindelse valgt fra vemurafinib, debrafinib, LGX818, trametinib, MEK162, LEE011, PD-0332991, panobinostat, verinostat, romidepsin, cetuximab, gefitinib, erlotinib, lapatinib, panitumumab, vandetanib, INC280, everolimus, simolimus, BMK120, BYL719 og CLR457.